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Abstract: Metabolic disorders have been identified as major health problems affecting a large portion
of the world population. In addition, obesity and insulin resistance are principal risk factors for the
development of cardiovascular diseases. Altered immune responses are common features of both
hypertension and obesity and, moreover, the involvement of the nervous system in the modulation of
immune system is gaining even more attention in both pathophysiological contexts. For these reasons,
during the last decades, researches focused their efforts on the comprehension of the molecular
mechanisms connecting immune system to cardiovascular and metabolic diseases. On the other
hand, it has been reported that in these pathological conditions, central neural pathways modulate
the activity of the peripheral nervous system, which is strongly involved in onset and progression
of the disease. It is interesting to notice that neural reflex can also participate in the modulation of
immune functions. In this scenario, the spleen becomes the crucial hub allowing the interaction of
different systems differently involved in metabolic and cardiovascular diseases. Here, we summarize
the major findings that dissect the role of the immune system in disorders related to metabolic and
cardiovascular dysfunctions, and how this could also be influenced by neural reflexes.
Keywords: obesity; hypertension; splenic immune system; neuroimmune interactions; autonomic
nervous system
1. Introduction
Despite initially having been depicted simply as a blood filter, the spleen is gaining more attention
for the pivotal role played in modulating immune responses [1]. The spleen is enclosed by an elastic
and fibrous capsule with emerging trabeculae directed toward the internal parenchyma, ensuring the
stability and maintenance of a well-organized structure [2,3]. The central arterioles that depart from
the splenic artery branch in the trabeculae to subsequently dive in the White Pulp (WP) area, which
contains B cells in the follicles and T cells. At this point, blood flows through the Marginal Zone (MZ)
that surrounds the WP, toward the Red Pulp (RP) area, where blood is directed to the venous sinuses
(Figure 1). Then, blood flows again through the trabecular area and is conveyed to the splenic vein.
The splenic RP oversees the blood filtration process, in which resident macrophages phagocyte old
erythrocytes, activate response to bacterial infiltration and allow iron recycling [1].
Another important activity that takes place in the RP is the production of antibodies. Indeed,
plasmablasts differentiate in response to a specific antigen within the WP. Plasmablasts show
enhanced production of CXC-chemokine receptor 4 (CXCR4), which specifically binds CXC-chemokine
ligand 12 (CXCL12), which is produced in large quantities in the RP and is responsible for the migration
and maintenance of cells in that splenic zone. This migration is also permitted due to the simultaneous
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repression of CXCR5 and CCR7 receptors on plasmablasts and lower response to the chemokines
responsible for the homing in the WP follicles and T cell zone [3,4].
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ligands CCL19 and CCL21 [3,5]. Mutations that abolish the expression of these chemokines and 
receptors determine a completely aberrant distribution of the immune cells in the correct splenic 
districts [5]. 
Finally, the MZ, separating White from RPs, represents a connection between circulating blood 
and immune cells. This architecture allows B cells to defend the organism from blood-borne 
pathogens, mainly generating different lines of immunoglobulins (IgA, IgM and IgG) [6]. 
Alternatively, MZ B cells are able to activate CD4+ T cells to become antigen presenting cells (APCs) 
[7]. Populations of immune cells present in the MZ are not limited to B cells. Indeed, subsets of 
Neutrophils [6], Dendritic Cells [8] and Macrophages [9] can be found in the same area of the spleen. 
In order to maintain the correct separation between the MZ populations and the WP and RP immune 
cell populations, a specific pattern of surface membrane receptors and a different expression of 
chemokines are needed [10]. 
In the last decades of the past century, researchers focused their attention on finding the basis of 
the immune system’s innervation, revealing that primary and secondary lymphoid organs receive 
fibers from the autonomic nervous system [11–14]. In particular, a variety of experimental approaches 
has been developed to deepen our understanding of the nature of splenic innervation [13]. It has been 
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and their synaptic endings are in close contact with immune cells [16–18]. Released neurotransmitters 
reach the surface of macrophages and/or lymphocytes, interacting with their specific receptors and 
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immune cells: White Pulp (WP) and Red Pulp (RP) with Sympathetic nerve fibers innervating
Marginal Zones (MZ).
Splenic WP is a lymphoid area in which the specific B cell receptor CXCR5 is responsible for
the organization of B cell follicles, where B cells are differentiated. T cells and Dendritic Cells (DCs)
expressing the CCR7 receptor are attracted and confined in the T cell zone by the CC-chemokine
ligands CCL19 and CCL21 [3,5]. Mutations that abolish the expression of these chemokines and
receptors determine a completely aberrant distribution of the immune cells in the correct splenic
districts [5].
Finally, the MZ, separating White from RPs, represents a connection between circulating blood
and immune cells. This architecture allows B cells to defend the organism from blood-borne pathogens,
mainly generating different lines of immunoglobulins (IgA, IgM and IgG) [6]. Alternatively, MZ B
cells are able to activate CD4+ T cells to become antigen presenting cells (APCs) [7]. Populations of
immune cells present in the MZ are not limited to B cells. Indeed, subsets of Neutrophils [6], Dendritic
Cells [8] and Macrophages [9] can be found in the same area of the spleen. In order to maintain the
correct separation between the MZ populations and the WP and RP immune cell populations, a specific
pattern of surface membrane receptors and a different expression of chemokines are needed [10].
In the last decades of the past century, researchers focused their attention on finding the
basis of the immune system’s innervation, revealing that primary and secondary lymphoid organs
receive fibers from the autonomic nervous system [11–14]. In particular, a variety of experimental
approaches has been developed to deepen our understanding of the nature of splenic innervation [13].
It has been widely described that sympathetic nervous system (SNS) fibers densely innervate the
spleen [15], and their synaptic endings are in close contact with immune cells [16–18]. Released
neurotransmitters reach the surface of macrophages and/or lymphocytes, interacting with their
specific receptors and modulating immune cells responses (i.e., inhibiting or enhancing expression
of different cytokines) [12,14,19]. These properties characterize the neuro-immune communication.
Once activated, immune cells produce and secrete a variety of pro- or anti-inflammatory mediators,
which provide a tuned immune cell response. Importantly, neuro-immune communications should
not be considered a one-way pathway from neurons to immune cells. It has been described that
a bi-directional communication does exist [20,21]. Not only neurotransmitters released by neuronal
Int. J. Mol. Sci. 2017, 18, 1216 3 of 12
terminations influence immune cells activity, but, in turn, cytokines released from immune cells can
influence functions of neurons via cognate receptors on the neuronal cell surface [22–24]. Indeed, T cells
are able to modulate noradrenaline (NA) pathways, reducing sympathetic fibers in the spleen and
affecting the pituitary-adrenal axis in central nervous system (CNS) through diminished hypothalamic
NA concentrations [24] (Figure 2).
In this view, the spleen appears as a crucial lymphoid organ, housing different populations of
monocytes and macrophages, with B and T lymphocytes allowing both innate and adaptive immune
responses. Besides this, the neuro-immune interaction provides a fundamental connection between the
resident immune cells and the adjacent fibers of the autonomic nervous system innervating the spleen.
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Figure 2. Bi-directional communication between the nervous and immune system. The scheme shows
an integrative interface between the sympathetic nervous system (SNS), the hypothalamic-pituitary-adrenal
(HPA) axis and the splenic immune reservoir. The SNS modulates immune cell activity through
noradrenaline (NA) released in the spleen; and, in turn, the SNS activity is regulated by IL-1 and TNF-α
cytokines, produced by splenic immune cells in a feedback loop manner. Paraventricular nucleus (PVN);
subfornical organ (SFO); central nervous system (CNS). Double arrow: neuronal projections; red arrow:
cytokine influence; black arrow: activation; dotted arrow: production.
2. Immune System and Metabolic Disease: Meta-Inflammation, Obesity and T2D, Adipokines
Obesity is a major health problem with growing incidence, especially in childhood, increasing
the possibility of developing, in adulthood, metabolic or cardiovascular co-morbidities such as type II
diabetes (T2D), atherosclerosis and hypertension [25–27]. Excessive nutrient intake and low energy
consumption with a consequential increase in adipose tissue size are conditions that could lead to
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obesity. In parallel with the incidence of obesity, patients frequently develop insulin resistance (IR),
a leading cause of type II diabetes (T2D). It is widely accepted that enhanced inflammation is a common
and central feature in metabolic syndrome. However, in contrast to the classic short-term inflammatory
response to infectious agents that is typically followed by a return to baseline conditions, metabolic
syndrome manifests alternative features of inflammation. A long-term and low-grade inflammation
characterizes the so-called “meta-inflammation” [28]. Derangement in the immune cells homeostasis
toward a steady increase in pro-inflammatory response is a key aspect that leads to the onset of such
pathophysiological conditions [29].
Studies conducted both in humans and animal models outline that obesity-induced inflammation
occurs in many organs involved in energy homeostasis: liver [30], muscle [31,32], pancreas [33],
and adipose tissue [34]. Metabolic dysfunctions affect not only peripheral organs but also the CNS,
especially in those hypothalamic areas involved in the control of energy balance, such as the arcuate
nucleus (ARC), the ventromedial, lateral and paraventricular hypothalamic nuclei [35–37].
Despite all the biological aspects connecting obesity with related diseases that have not
already been discovered, several studies have emphasized the relationship between obesity-induced
pro-inflammatory response and the onset of metabolic syndrome. In order to investigate the causes
of obesity-induced inflammation and IR, researchers at first focused their attention on fat pad.
Lean adipose tissue is normally populated by different innate and adaptive immune cells, designated
to maintain an anti-inflammatory phenotype and tissue integrity [38]. In addition, they have been
shown to secrete anti-inflammatory cytokines with the aim of promoting insulin sensitivity, lipolysis,
mitochondrial respiratory capacity, oxygen consumption and inhibiting lipogenesis [39].
Conversely, obesity provides conditions under which adipose tissue changes, altering the
functions of immune cells, which contributes to the derangement of a balanced type-1 and type-2
immunity [29]. Importantly, murine models and human studies demonstrate that the quantity of
adipose tissue macrophages (ATMs) bears a close relationship with the amount of adipose tissue itself.
Specifically, ATMs in lean mice account only for 10% of cells in the adipose tissue, and are
evenly dispersed. In the lean state, macrophages express specific anti-inflammatory markers, such as
MGL1 (macrophage galactose N-acetyl-galactosamine specific lectine 1), Arginase1, CD301, CD206
and CD163 on their cellular surface [40–42]; and the anti-inflammatory environment is maintained
through the secretion of anti-inflammatory cytokines IL-4 (produced also by eosinophils), IL-13 and
IL-10, with CD4+Foxp3+ regulatory T cells improving insulin sensitivity [29,40,42,43]. Since the
controlled expression and secretion of anti-inflammatory mediators is pivotal to maintaining basal
immune homeostasis in adipose tissue, ATMs and regulatory T cells are not the only cell types homing
in on the adipose tissue of lean mice. Recently, a population of innate-like B, similar to B-1a and
B10 B cells, has been identified in the visceral adipose tissue (VAT) of lean mice [44]. These cells,
producing high amounts of IL-10, are critical players in maintaining the correct balance of immune
cell populations toward an anti-inflammatory environment. The surgical procedure of splenectomy
provided important evidence that the spleen is involved in the modulation of immune balance,
being the source of innate-like B cells [44]. VAT of high fat diet (HFD)-fed splenectomized mice
indeed showed reduced levels of innate-like B cells compared to sham mice, whereas the number
of other lymphocytes was comparable [44]. In agreement, adoptive transfer of innate-like B cells in
obese mice ameliorated both insulin sensitivity and glucose tolerance [44]. Others have discovered
a different B cell population, called adipose natural regulatory B cells (Breg) [45]. This subset has
been found to be crucial in decreasing CD44 and interferon-γ (IFN-γ) production in CD8+ T cells
within visceral and subcutaneous fat depots. In addition, these cells were shown to improve IR
by ameliorating tissue homeostasis through the constitutive production of IL-10, both in mouse
models and in humans [45]. Through experiments of adoptive transfer of adipose tissue B cells
in diet-induced obesity (DIO) mice, it has been demonstrated that Breg cells of non-splenic origin
were found in adipose tissue, pointing out the possible presence of other routes of recruitment [44].
In a different work, it was shown that B cells are involved in the onset of inflammation and IR upon HFD
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feeding, promoting the release of CD4+ and CD8+ T cells cytokines and IgG2c pathogenic antibodies
both in mouse models and in humans [46]. In addition, the IgGs produced enhanced the switch of
macrophages toward pro-inflammatory phenotypes, thus contributing to development of metabolic
disorders [46]. This evidence highlights the fact that the surveillance of systemic immune homeostasis
is granted by specific populations of B and T cells, which in part are provided by a secondary lymphoid
organ, the spleen, that preserves an anti-inflammatory immune environment. On the other hand,
the existence of B cell subpopulations that expand, boosting the early phase of inflammation in obesity,
demonstrates that B cells are also involved in the first stage of metabolic syndrome with the production
of autoantibodies.
In obesity, the immune scenario completely changes through the massive production and
secretion of chemoattractant molecules or pro-inflammatory cytokines. Adipocytes progressively
increase in number and dimension. Macrophages with a pro-inflammatory phenotype massively
infiltrate the adipose tissue and, along with resident ATMs, begin pathological proliferative processes.
The percentage of ATMs rises to 40–50%, and they are specifically detected surrounding the necrotic
and enlarged adipocytes, forming typical “crown-like structures” (CLSs) [40,47–49]. ATMs confined
in these structures are characterized by membrane expression of specific pro-inflammatory markers,
such as CD11c, TLR4, and a reduced production of anti-inflammatory cytokine IL-10 [40]. In addition,
ATMs (CD11c+CD206−) stimulated with pro-inflammatory cytokines such as IFN-γ, in turn produce
abundant factors including TNF-α, IL-1β, IL-6 and nitric oxide (NO) [46,50]. A different study with
HFD-fed mice showed that more pro-inflammatory F4/80+CD11c+ macrophages were recruited
in adipose tissue of obese mice compared with lean mice and, conversely, HFD-fed C–C motif
chemokine receptor 2 (CCR2) KO mice showed a decreased content of the same population of immune
cells, thus suggesting that infiltrating cells were recruited through a mechanism mediated by the
chemokine monocyte chemoattractant protein-1 (MCP1/CCL2) and CCR2 [38]. The progressive ATM
accumulation in adipose tissue and the proportional increase in inflammatory mediator production
give rise to a cascade of transcription factor activations and other pro-inflammatory cell recruitments,
which dramatically and further strengthen the inflammatory response and progression of metabolic
syndrome. Wu et al. demonstrated that, in obesity, the enrollment of splenic innate-like B cells,
along with their anti-inflammatory activity, is not sufficient to counteract the rising inflammation
and IR development [44]. With developing obesity, CD4+Foxp3+ regulatory T cells are no longer
able to counteract pro-inflammatory IFN-γ secreting CD8+ and CD4+ T cells [28]. Natural killer
(NK) cells in visceral adipose tissue are stimulated, in obesity, to produce IFN-γ, participating to
the inflammatory response. Mice that were deficient of NK cells, adipocyte NK-activation receptors
(NCR-1) or IFN-γ, demonstrated reduced recruitment of pro-inflammatory macrophages in VAT and
ameliorated obesity-induced IR [51]. In contrast, IL-15-induced NK cells aggravated metabolic disease,
favoring IR and adipose tissue inflammation [52]. As a further mechanism modulating the immune
response involved in metabolic disease, it has been shown that adipose tissue releases free fatty acids
(FFAs), which enhance inflammation trough Toll-like receptor 4 (TLR4) via Fetuin-A (FET-A) and the
consequent activation of Nuclear factor KB (NF-KB) induced IR. In addition, it has been reported that
expression of both FetA and TLR4 is essential for development of IR in the presence of FFAs [53].
Taken together, these findings suggest that the immune system plays a fundamental role in
the maintenance of the homeostatic physiological environment. However, in response to specific
stimuli, a dysregulation of the immune system may become a principal actor in the development of
metabolic syndrome.
3. Metabolic Disease as a Risk Factor in CVD and Hypertension
In the contest of obesity, an abnormal increase of adipose tissue has been correlated with
a concomitant increased risk of cardiovascular disease (CVD) incidence. Moreover, the contribution
of different adipose depots in the development of obesity-related diseases has been investigated.
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Different studies on humans and mouse models, in fact, ascribe to VAT—and not to Subcutaneous
Adipose Tissue (SAT)—a predominant role in IR and CVD [54–56].
As described above, adipose tissue can not only be considered as a place where energy is
preserved but, notably, it also has endocrine activity producing a wide range of molecules involved
in metabolic processes [37]. The proteins that exert immuno-metabolic or cardiovascular functions,
and are produced and secreted by adipose tissue, are also known as adipokines. These molecules
carry out their effects modulating appetite and energy expenditure, insulin and glucose metabolism,
as well as blood pressure, reaching the CNS and acting on neurons in specific brain areas. On this
note, the melanocortin system resides in the hypothalamus and acts as a fulcrum of energy balance
regulation [57]. Two different populations of neurons participate with opposite roles in the control of
energy balance: on one hand, the orexigenic agouti-related peptide (AgRP) and neuropeptide (NPY)
neurons; on the other, the anorexigenic proopiomelanocortin (POMC) neurons, whose activity can be
directly regulated by metabolic hormones [57] and inflammatory molecules [35].
As a consequence of obesity, an immune regulator as important as IKKβ/NF-κB is involved not
only in meta-inflammation of peripheral tissues, but is also activated in the CNS, participating in
hypothalamic inflammation and aggravating IR and Leptin resistance development [35]. Leptin has
been one of the first and most-analyzed adipokines. It is a hormone specifically expressed by adipose
tissue, and its production is proportional to the quantity of fat pad [58]. The main role exerted
by Leptin is the regulation of energy balance, acting directly in the CNS, and being able to cross
the blood brain barrier (BBB) [59,60]. Besides its effect on energy control, Leptin is involved in
the CNS modulation of sympathetic nerve activity (SNA). Targeted deletion of the Leptin receptor
(ObR), specifically in the ARC, blocks diet-induced increased renal sympathetic activity and blood
pressure rise [61]. Another study links Leptin action to the circumventricular subfornical organ (SFO),
highlighting that deletion of Leptin receptors (ObR) in the SFO did not affect food intake behavior in
mice, but suppressed SNA [62]. Studies conducted in both humans [63–66] and DIO mouse model
clearly showed that, during obesity, the higher level of Leptin concentration correlated with SNA in
renal nerves and blood pressure increase [67,68]. Thus, it is clear that obesity-related adipokines sustain
neuroinflammation affecting many brain areas and producing different deleterious consequences to
systemic homeostasis beyond feeding behavior and energy imbalance.
To date, many studies have described that the modulation of renal sympathetic activity is strictly
related to hypertension induced by several pathophysiological alterations, like obesity [69]. However,
it has recently been uncovered that sympathetic outflow plays a crucial role in hypertension, even
directly modulating immune function though a control of splenic sympathetic nerve activity [12,13].
With obesity being characterized by chronic low-grade inflammation, and at same recognized as
a dominant risk factor for hypertension, studies aimed at discerning the possible role of the neural
modulation of splenic immunity in affecting the metabolic and cardiovascular consequences of the
disease are warranted.
4. Neural Regulation of Immunity in Hypertension
The fact that immune cells and the sympathetic nervous system (SNS) strongly contribute to
hypertension is a well-consolidated notion but, more recently, it has also been highlighted that these two
elements are strictly intertwined in the modulation of blood pressure regulation. By using RAG-1−/−
mice, lacking both B and T cells, it was firstly shown that lymphocytes, infiltrating tissues typically
targeted by increased blood pressure levels, are essential for the onset of hypertension [70]. In the
same experimental setting of Angiotensin (AngII)-induced hypertension, it has been demonstrated
that the T cells found in target tissues as kidneys and vasculature originate in the spleen [12].
In particular, by taking advantage of mice differing for the leukocyte antigen CD45, expressed in
the two isoforms CD45.1 and CD45.2 in two different strains, it was possible to generate chimeric
animals by spleen transplantation in order to label T cells of splenic origin with the CD45.1 marker
(CD45.1 donor mouse), differentiating them from those of the recipient mouse (CD45.2 positive).
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After infusion of AngII, T cells infiltrating aorta and kidneys were found to be positive for both CD45.1
and CD45.2 antigens, thus indicating that the hypertensive challenge recruited a movement of immune
cells from the spleen to allow colonization of target organs [12]. However, whether an immune
response originating in the spleen is also recruited in hypertension resulting from other causes, such
as that reproduced with deoxycorticosterone acetate (DOCA)-salt or obesity murine models, is still
unknown. Certainly, the recently discovered neural regulation of immunity during AngII-hypertensive
challenge is suggestive that molecular mechanisms activated in the spleen to prime immunity could be
shared by various stimuli capable of exerting a neurogenic action [12,13,71,72]. On this note, the fact
that chronic hypertensive stimuli, such as AngII and DOCA-salt, cause an increase of blood pressure
levels activating renin-angiotensin system (RAS) in the brain through the AngII type 1 receptors
(AT1Rs) in the SFO is well known [72]. This observation fits well with more recent evidence that
both AngII and DOCA-salt activate an increased sympathetic outflow in the spleen [13], suggesting
that, overall, different hypertensive challenges share neurogenic mechanisms to prime the immune
system through neuroimmune pathways. Conversely, to date, there is still no evidence of the possible
involvement of this neuroimmune pathway in the development of arterial hypertension associated
with metabolic syndrome.
It is interesting to note that Harlan and colleagues, some years ago, demonstrated that the
intracerebroventricular (ICV) administration of Leptin in the ARC of mice was able to significantly
increase the renal sympathetic nerve activity, leading to arterial hypertension [61]. In light of current
knowledge of neuroimmune pathways that are activated by sympathetic outflow in the spleen and are
crucial for the onset of hypertension, it could be envisaged that even metabolic stimuli could share
similar neurogenic mechanisms coupled with immune priming to increase blood pressure [62].
On a different note, immunologists discovered for the first time that the autonomic nervous
system has a critical role in modulating immune responses in infectious settings. Several years ago,
Tracey and colleagues published an amazing work that provided the basis for unraveling a circuit
that connects the brain to the spleen and is able to dampen exacerbated innate immune responses
during endotoxemia [17]. In particular, they showed that the electrical stimulation of the vagus nerve
was effective for hampering the excessive TNF-α production induced by Lipopolysaccharide (LPS)
administration in mice [17]. It was also proved that this pathway was mediated by α7-nicotinic
cholinergic receptors (α7nAChRs) expressed on macrophages in the spleen, supporting the existence
of the so-called “cholinergic anti-inflammatory reflex” [17].
Some other evidence, showed that the peripheral administration of the acetylcholinesterase inhibitor
galantamine, typically used for the treatment of neurological disorders [73,74], has an anti-inflammatory
effect, reducing serum TNF levels in endotoxemic mice [74]. Surprisingly, a similar galantamine
treatment was shown to ameliorate inflammation and obesity in mice, significantly improving blood
glucose and IR [75]. Indeed, mice fed with HFD and concomitantly treated with chronic galantamine
exhibited a reduction of circulatory cytokines and adipokines, specifically IL-6 and Leptin [75]. Overall,
these reports suggest that further insight is required to understand how neuroimmune mechanisms
modulate metabolic, and probably cardiovascular, dysfunction in obesity.
Adipose tissue growth is closely related to angiogenesis [76]. Besides its role in secreting
adipokines, regulating feeding behavior, and modulating SNA, Leptin plays an important role
in angiogenesis, too [76]. During obesity, fat depots also produce other molecules involved
in angiogenesis, such as the Vascular Endothelial Growth Factor (VEGF) [76], or the Placental
Growth Factor (PlGF) [77], which belong to the family of the Vascular Endothelial Growth Factors
(VEGFs). These growth factors have been considered novel therapeutic targets for the treatment
of human obesity, given results obtained in experimental models suggesting the protective roles of
antiangiogenic molecules, highlighting their potential therapeutic application [76]. On a similar note,
the more recent role proposed for PlGF as a modulator of inflammatory and immune responses in
cardiovascular settings further suggests that its involvement in metabolic syndrome could deserve
further investigation, being involved in roles other than angiogenesis [78–80]. Indeed, the fact that PlGF
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has also been shown to play a pivotal role in the onset of hypertension, by mediating neuro-immune
interactions in the spleen [12], suggests the possibility that its implications in obesity could also be
related to the cardiovascular consequences of metabolic alterations, as is the case for increased risk
of hypertension itself. A report in the literature suggests that the inactivation of PlGF in a murine
model of HFD-induced obesity leads to reduced adipose tissue growth with a concomitant reduction
of angiogenesis [77]. In ob/ob mice, a murine model of obesity characterized by mutations in the
gene responsible for the production of Leptin, the absence of PlGF significantly prevented weight
gain [81]. However, as mentioned above, obesity is also strictly related to chronic inflammation
and increased risk of developing cardiovascular disease [47,48], thus suggesting the need to explore
possible roles of angiogenic growth factors in mediating the immune functions involved in obesity
and related complications.
5. Conclusions
Obesity and related metabolic disorders are recognized as risk factors for the onset of
cardiovascular diseases, and hypertension in particular. Both these conditions share complex and
not-yet-completely-understood aspects. The immune system is not only the main player responsible
for preserving the host from exogenous hostile infiltration, but increasing evidence sustains the
idea that it is also involved in the regulation of multiple biological aspects. Derangements in
the homeostasis of immune components are pivotal factors in the onset of metabolic diseases and
end-organ damage in hypertension. Despite this, the origin and the activation pathways of infiltrating
immune cells in a multifactorial disease, such as metabolic syndrome, have not been fully described yet.
However, impaired activity of the autonomic nervous system has been deepened in response to several
metabolites produced during obesity and insulin resistance. The recent discovery of a neuro-immune
interaction that primes activation and migration of splenic immune cells has revealed that the nervous
system modulates immunological responses evoked by hypertensive stimuli. Therefore, it can
be hypothesized that the same neuro-immune communication in this secondary lymphoid organ
contributes to the refueling of pathological immune cells in adipose tissue during metabolic disease.
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